letter to the shareholders

Editorial

Back to the Future

You probably have to come face-to-face with death to learn to fully savor life; frankly, one has to wonder if all of humanity hasn't been living by that maxim for the past three years.

Trump has officially reinstated the law of the jungle as the world's new operating principle—goodbye to law, values, morality, and truth…. We are entangled in a completely grotesque world with no end in sight, caught between the absurdity, cruelty, and greed of the leaders of the neo-reactionary global superpowers, who are attempting to carve up the world, taking advantage of the culpable weakness—even the cowardice—of European democratic states. Everything is in place for our future to be played out like Russian roulette… It's a shame, because it is life that gives meaning to death, not the other way around.

Like biotech companies, Ukraine has become the Western world's "military startup"—facing the same funding struggles and the same chaotic journey, full of ups and downs in the race for technology, only to have its fate sealed by a more powerful force, despite the talent of its CEO-President and, above all, the lives sacrificed.

Should we believe in miracles as a last resort?

The concept of a miracle is driven by the hope of changing the future through the intervention of resources unknown to science. The concept of a miracle stands in opposition to rationality and ultimately opens the door to spirituality. Is our destiny predetermined, or are we in control of it?

In healthcare, for example, probabilities are challenges to be met individually by each patient and scientist. They are based on the past and on populations, individual cases, and new developments—all of which are excluded at a given moment. Every patient afflicted by a serious illness draws upon immense courage to push back against the inevitable by mobilizing their body, intellect, spirit, and the advances of science. It is a fact that there may be "miracles" that science cannot explain at the moment.

Returning to humanity, I wish it much courage to recover as quickly as possible from the damage caused by this new world order at the dawn of the 21st century. The miracle would be for democratic Europe to finally assert itself as a coherent and respected global power. Should we wait for a miracle?

For OPM, 2025 was yet another "annus horribilis"; Servier's withdrawal from our OPM-201 program in late 2024 forced us to reevaluate our entire development strategy and prematurely embark on a search for funding and partners in a general climate that was extremely closed off. The pharmaceutical industry and investors have retreated to their core areas and now demand proof of concept in patients, a step further than where we currently stand. We have never given up, as we remain highly confident in the therapeutic potential of our two products in development. Months went by; we held numerous meetings and made countless contacts without success, despite the interest generated, yet the teams never stopped their painstaking work. Those familiar with Oncodesign's 30-year journey know that its culture is to never give up, even when the signs point to an impending crash.

Today, OPM enjoys major international recognition, highlighted by the interest shown in our OPM-201 compound by the Michael J. Fox Foundation (MJFF), the most influential institution in research for new treatments for Parkinson's disease. The Foundation, impressed by our project, is funding the continued development of OPM-201 through a $6.9 million grant, intended to cover the necessary CMC work as well as long-term preclinical toxicology studies. Perhaps this is the "miracle made in the USA."

Our current efforts remain focused on securing new funding to carry out the two Phase 2a trials (OPM-101, June 2026; OPM-201, early 2027) required to validate these future drugs, as requested by the pharmaceutical industry and investors seeking more mature results.

This international recognition represents a major turning point and opens up new prospects for OPM. 2026 thus looks promising for the company and for patients who are eagerly awaiting these new therapeutic solutions.

Philippe GENNE
Chairman and CEO

CONTENTS

OPM's mission

Discover and **Develop new innovative therapies** effective against advanced and resistant cancers through **precision medicine** addressed against the phenomena of therapeutic resistance and metastatic development.

Karine Lignel – Chief Operating Officer, Co-founder
Philippe Genne – Chairman and CEO, Co-founder
Jan Hoflack – Chief Scientific Officer, Co-founder

The Michael J. Fox Foundation has awarded $6.9 million in funding to accelerate the development of an innovative treatment for Parkinson's disease - Project LARKIN

Zoom on the Michael J. Fox Foundation

THE MICHAEL J. FOX FOUNDATION
FOR PARKINSON'S RESEARCH

The foundation was created **in 2000 by actor Michael J. Fox,** who was diagnosed with Parkinson's disease at the age of 29

The foundation **is the world's largest nonprofit organization** dedicated to funding research on Parkinson's disease

Since its creation, the Foundation has provided **more than $800 million** in support of global research

In a context where Parkinson's disease remains a major medical challenge—both due to its growing prevalence and the lack of disease-modifying treatments—OPM continues, following the transfer of all assets from this program back to Servier, **the development of OPM-201, its LRRK2 kinase inhibitor intended for the treatment of Parkinson's disease.**

This is the context for the funding recently secured from the **Michael J. Fox Foundation for Parkinson's Research (MJFF)**, one of the most committed international organizations in research on this disease.

OPM has secured $6.9 million in funding for the LARKIN project.

The LARKIN project aims to fund a decisive stage in the development of OPM-201, which has already successfully completed an initial clinical phase (Phase 1) in healthy volunteers, demonstrating a favorable safety profile, good brain penetration, and robust inhibition of its biological target. The funding will help overcome the final hurdles required before prolonged administration in patients.

Allocation of funds to two complementary strategic areas

1. **The first area** concerns chemistry, manufacturing, and control (CMC) activities. This involves producing the clinical pharmaceutical forms of OPM-201 (tablets) intended for a future Phase 1b clinical trial in patients with Parkinson's disease as well as a future Phase 2 trial. This work includes manufacturing under GMP conditions, long-term stability studies, and the preparation of clinical batches and associated placebos. Attention is being paid to optimizing the use of OPM's existing stock of active substance (over 60 kilograms), which has already been produced to high industrial standards, to maximize value creation and limit industrial risks. This first focus area will also enable the production of the reagents necessary for the second focus area.

2 **The second major area** of funding focuses on conducting a long-term toxicology study, which is essential to enable chronic exposure to the treatment in later clinical phases (Phase 2 and beyond). This regulatory study, conducted over nine months in animals in accordance with international standards, aims to demonstrate the safety of OPM-201 during prolonged administration. Its design will be validated with European and U.S. regulatory agencies. Its completion will mark a key milestone in the program, paving the way for longer clinical trials with greater potential for value creation.

The most critical phases of the LARKIN project will take place over 30 months; the CMC portion beyond the 30-month mark will consist solely of stability studies. At the same time, OPM is working on the Phase 1b clinical trial, the primary objective of which will be to demonstrate safety and identify the appropriate dose of OPM-201 in patients with Parkinson's disease.



Beyond its financial contribution, the MJFF **plays a central role in the global Parkinson's disease research ecosystem**. It prioritizes support for projects with high translational potential, capable of rapidly yielding tangible benefits for patients. Its involvement alongside OPM is an independent validation of the scientific and medical relevance of OPM-201. The Foundation also spearheads international collaborative clinical platforms, offering unique opportunities to accelerate clinical development, with which OPM is now associated.

For our shareholders, securing this funding is fully in line with the Company's development strategy: reaching key value milestones, reducing technical and regulatory risks, and positioning OPM-201 as an attractive asset for partnerships or licensing.

The LARKIN project illustrates OPM's ambition to develop therapeutic solutions that can have a lasting impact on patients' lives.

OPM and Ksilink Launch a Collaborative Program to Accelerate the Discovery of New Therapies for the Central Nervous System

Ksilink is a Strasbourg-based company **that develops and operates a patient-derived phenotypic screening platform.**

Its technology is based on advanced cellular models derived directly from patients, enabling the accurate reproduction of the biology of complex diseases.

Using high-content screening, Ksilink analyzes the effect of molecules on numerous cellular parameters simultaneously, capturing subtle phenotypes relevant to the disease. This approach enables the identification of drug candidates with real translational potential, which is often difficult to detect using traditional methods focused on a single target.

The company focuses primarily on neurodegenerative disorders, neurodevelopmental diseases, metabolic diseases, and other complex pathologies.

Oncodesign Precision Medicine (OPM) is partnering with Ksilink to evaluate its Nanocyclix® compound library in advanced patient-derived cellular models that accurately replicate the biology of central nervous system diseases.

This collaboration combines the selectivity and potency of Nanocyclix® macrocyclic small molecules with Ksilink's high-content phenotypic screening technology.

The goal is to identify new molecules capable of modulating key cellular mechanisms involved in neurodegenerative and neurodevelopmental disorders, in order to select the most promising candidates for preclinical programs and, ultimately, for the development of new therapeutic options.

OPM has been granted a patent for its new macrocyclic LRRK2 kinase inhibitors

Patent WO2021224320, covering new macrocyclic inhibitors of LRRK2 kinase, a key target in Parkinson's disease, is currently under examination in more than 50 countries and regions. This innovation is based on the proprietary Nanocyclix® platform and represents a breakthrough in the development of selective and potent drug candidates to modulate LRRK2, an enzyme involved in the progression of neurodegenerative disorders.

Between October 2025 and February 2026, Oncodesign Precision Medicine secured patent approval in several major markets (China, Europe, Japan, and the United States). The intellectual property protection granted strengthens OPM's position in the field of targeted therapies for the central nervous system and paves the way for future preclinical and clinical developments, particularly in familial and idiopathic forms of Parkinson's disease.

OPM wins the healthtech innovation award

OPM won the **HealthTech Innovation** award at the 2025 Innovation Awards ceremony organized by La Banque Postale Asset Management.

Represented by Karine Lignel before in front of highly qualified experts, and following a rigorous selection and review process, OPM stood out for its **expertise in precision medicine for the treatment of resistant and metastatic cancers.**

OPM's stock price performance over the past year



Stock market information

ISIN Code	FR001400CM63
Number of shares	19 136 125
Market capitalization*	9.2 M€
Share price*	0.478€

ELIGIBLE PEA PME

data as of 16/04/2026 after market close

To receive all the latest news from Oncodesign Precision Medicine in real time, and to subscribe to our newsletter, send us your e-mail address at oncodesign@newcap.eu.

CONTACT

OPM
Karine LIGNEL
Executive Vice-President
+33 (0)3 10 45 18 20
investisseurs@oncodesign.com

NewCap
ShareholdersRelations
Mathilde BOHIN / Alban DUFUMIER
+33 (0)1 44 71 94 95
oncodesign@newcap.eu